Affinage

PUM1

Pumilio homolog 1 · UniProt Q14671

Length
1186 aa
Mass
126.5 kDa
Annotated
2026-06-10
54 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PUM1 is a sequence-specific RNA-binding protein that recognizes a UGUAHAUA consensus motif in the 3' UTRs of target mRNAs and acts as a dose-sensitive post-transcriptional repressor controlling cell proliferation, innate immunity, and development (PMID:18411299, PMID:29474920). Mechanistically, PUM1 destabilizes bound transcripts by recruiting the CCR4-NOT deadenylase complex (not the PAN deadenylase) in a poly(A)-tail-dependent manner, and its repressive output is continuously tunable: phosphorylation within PUM1's intrinsically disordered regions graded­ly modulates multivalent CCR4-NOT binding, and rising PABPC1/PABPC4 concentrations protect the poly(A) tail to dampen PUM1 activity [PMID:bio_10.1101_2025.10.02.680050, PMID:bio_10.1101_2024.10.18.618793]. PUM1 can also repress targets at the translational level without altering mRNA abundance, as shown for CDKN1B/p27, and can cooperate with NANOS cofactors to confer target specificity (PMID:34531333, PMID:30269240, PMID:35743036). Through CDKN1B/p27 repression PUM1 promotes the G1-S transition and controls postnatal growth, a relationship established by genetic epistasis in which Cdkn1b loss rescues Pum1-null growth defects (PMID:30811992). Beyond proliferation, PUM1 restrains innate immunity by repressing LGP2 to suppress a two-phase interferon cascade (PMID:28760986), suppresses TLR4-NF-κB signaling to protect against oxidative senescence (PMID:35034101), and represses γ-globin (HBG1) to drive fetal-to-adult hemoglobin switching during erythroid differentiation (PMID:35667093). PUM1 expression is itself regulated by upstream factors including KLF1 in erythroid cells and HIF1α under hypoxia (PMID:35667093, PMID:41135634). PUM1 haploinsufficiency, through reduced protein levels that correlate with phenotypic severity, causes a dose-dependent neurological disorder (PMID:29474920).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2008 High

    Established the founding biochemical identity of human PUM1: what sequence it recognizes and what it does to bound transcripts.

    Evidence Genome-wide RIP-microarray plus knockdown mRNA-stability assays and stress granule immunofluorescence

    PMID:18411299

    Open questions at the time
    • Did not resolve the deadenylase machinery used for decay
    • Translational repression inferred from localization, not directly measured
  2. 2019 High

    Connected PUM1 to a defined proliferative output by showing it represses CDKN1B/p27 and that this relationship is genetically epistatic for growth control.

    Evidence Pum1/Pum2 knockout mice, 3' UTR reporters, and Pum1-/- x Cdkn1b-/- double-mutant rescue

    PMID:30811992

    Open questions at the time
    • Did not separate translational vs decay contributions at CDKN1B in vivo
    • Tissue specificity of the epistasis not fully mapped
  3. 2017 High

    Defined PUM1 as a negative regulator of innate immunity by placing LGP2 as the direct downstream mediator of a two-phase interferon cascade, distinguishing PUM1 from PUM2.

    Evidence Combinatorial siRNA epistasis (PUM1+LGP2), interferon functional assays, HSV-1 replication, PUM2 negative control

    PMID:28760986

    Open questions at the time
    • Direct PUM1 binding to LGP2 3' UTR not biochemically shown in this study
    • Physiological trigger that relieves PUM1 repression unknown
  4. 2018 High

    Established PUM1 as a dose-sensitive repressor whose protein level quantitatively determines phenotypic severity, linking it to human disease.

    Evidence Patient-derived cells with quantitative protein/target measurements and dose-response correlation across patients

    PMID:29474920

    Open questions at the time
    • Which neuronal targets drive each phenotype not fully resolved
    • Molecular basis of missense-induced protein destabilization not characterized
  5. 2020 High

    Showed PUM1 controls a discrete decay regulon coupled to DNA damage, defining a context where PUM1 abundance is itself regulated to alter target stability.

    Evidence Transcriptome-wide stability profiling plus RIP-seq, with cisplatin sensitivity and DNA synthesis assays

    PMID:32375027

    Open questions at the time
    • Mechanism reducing PUM1 abundance after DNA damage unresolved
    • Direct binding to all 48 targets not individually validated
  6. 2022 High

    Demonstrated PUM1 represses HBG1 to govern hemoglobin switching and is transcriptionally driven by KLF1, embedding it in erythroid gene regulation.

    Evidence RIP, mRNA stability and translational efficiency assays, erythroid knockdown, plus a patient with an RNA-binding-domain mutation and elevated HbF

    PMID:35667093

    Open questions at the time
    • Relative weight of decay vs translational repression at HBG1 not quantified
    • Whether HbF derepression is therapeutically tractable not addressed
  7. 2022 High

    Linked PUM1 to TLR4-NF-κB-driven cellular senescence, defining a protective post-transcriptional axis confirmed in disease models.

    Evidence RIP and 3' UTR binding, bidirectional manipulation with NF-κB readouts, and in vivo osteoarthritis gene therapy

    PMID:35034101

    Open questions at the time
    • Whether repression is translational or decay-based at TLR4 not dissected
    • Upstream control of PUM1 in senescence unknown
  8. 2018 Medium

    Revealed that PUM1 specificity and cofactor cooperation diverge from PUM2, including PBE-independent repression and NANOS3 partnership.

    Evidence Reporter assays with PBE-mutant 3' UTRs, EMSA, and NANOS paralog co-repression assays

    PMID:30269240

    Open questions at the time
    • Structural basis of PBE-independent binding not defined
    • Single target (SIAH1) and single lab
  9. 2020 Medium

    Showed PUM1 and PUM2 build distinct RNP networks with different cofactors and target pools, formalizing paralog functional divergence.

    Evidence RIP-seq, RNA-seq, and mass spectrometry interactome in TCam-2 germ cells

    PMID:32316190

    Open questions at the time
    • Single cell model limits generality
    • Functional consequences of distinct cofactor sets not tested
  10. 2024 Medium

    Provided the structural-biochemical basis for how PUM1 recruits CCR4-NOT and how phosphorylation tunes deadenylation in a graded manner.

    Evidence Structural biology and reconstituted in vitro deadenylation with phosphomimetic/phosphoablative IDR variants (preprint)

    PMID:bio_10.1101_2024.10.18.618793

    Open questions at the time
    • Preprint, not peer-reviewed
    • Kinases responsible for PUM1 IDR phosphorylation in vivo not identified
  11. 2025 Medium

    Defined the deadenylase requirement and PABPC-based tunability of PUM1-mediated decay, completing the core repression mechanism.

    Evidence Biochemical reconstitution, deadenylase-requirement assays, PABPC co-IP and titration (preprint)

    PMID:bio_10.1101_2025.10.02.680050

    Open questions at the time
    • Preprint, not peer-reviewed
    • Whether PABPC tuning operates at endogenous targets in cells not shown
  12. 2025 Medium

    Expanded the regulatory hierarchy by showing HIF1α transcriptionally induces PUM1 to destabilize KCNK3 in pulmonary hypertension.

    Evidence ChIP for HIF1α-promoter binding, RIP, mRNA stability assays, and AAV9 in vivo knockdown in rat PH models

    PMID:41135634

    Open questions at the time
    • Single lab
    • Translational vs decay contribution at KCNK3 not separated
  13. 2023 Medium

    Showed PUM1 can stabilize rather than degrade certain targets (DEPTOR), revealing context-dependent positive regulation feeding into PI3K-Akt/glycolysis.

    Evidence RIP, RNA-seq, metabolomics, and in vitro/in vivo knockdown in gastric cancer

    PMID:37469018

    Open questions at the time
    • Mechanism by which PUM1 stabilizes (vs destabilizes) DEPTOR unresolved
    • Single lab and cancer-specific context

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PUM1 switches between destabilizing and stabilizing target mRNAs, and which upstream kinases set its phosphorylation-dependent activity in specific cell types, remain unresolved.
  • No unified model reconciling decay (e.g. HBG1, KCNK3) vs stabilization (DEPTOR, PAK6) outcomes
  • Kinases and signals controlling PUM1 IDR phosphorylation in vivo unidentified
  • In-cell validation of PABPC tunability still pending peer review

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 7 GO:0140098 catalytic activity, acting on RNA 3 GO:0048018 receptor ligand activity 2 GO:0098772 molecular function regulator activity 2
Localization
GO:0005829 cytosol 1 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-8953854 Metabolism of RNA 4 R-HSA-168256 Immune System 3 R-HSA-1640170 Cell Cycle 2
Partners
DDX5NANOS3PABPC1PABPC4PUM2
Complex memberships
CCR4-NOT deadenylase complexNANOS3-PUM1 repressor complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 Human PUM1 binds a core consensus sequence UGUAHAUA in the 3' UTR of target mRNAs and enhances their decay; PUM1 also relocalizes to stress granules, suggesting a role in translational repression. Genome-wide ribonomic analysis identified mRNAs enriched for transcriptional regulators and cell cycle/proliferation factors as PUM1 targets, and PUM1 knockdown demonstrated increased stability of associated mRNAs. RNA immunoprecipitation (RIP) followed by microarray (ribonomic analysis); PUM1 knockdown with mRNA stability assays; immunofluorescence for stress granule localization Molecular and cellular biology High 18411299
2018 PUM1 haploinsufficiency causes upregulation of known PUM1 target mRNAs/proteins in patient-derived cells; missense mutations reduce PUM1 protein levels (~25% reduction for adult-onset, ~50% reduction for infantile-onset disease), and the degree of reduction correlates with phenotypic severity. This establishes PUM1 as a dose-sensitive posttranscriptional repressor of its target mRNAs in neurons. Patient-derived cell studies; protein level quantification (Western blot); measurement of target mRNA/protein levels Cell High 29474920
2019 PUM1 (and PUM2) repress translation of CDKN1B (p27) by binding Pumilio binding elements (PBEs) in the 3' UTR, promoting G1-S transition and cell proliferation. Cdkn1b deficiency partially rescues the postnatal growth defects of Pum1-/- mice, establishing a genetic epistasis relationship. Pum1/Pum2 knockout mouse models; 3' UTR reporter assays; genetic rescue experiments (Pum1-/- × Cdkn1b-/- double mutants); Western blot for CDKN1B protein Cell reports High 30811992
2019 PUM1 knockdown in pancreatic cancer cells activates the PERK/eIF2/ATF4 signaling pathway, as shown by increased levels of p-PERK, p-EIF2A, and ATF4. PUM1 levels negatively correlate with p-PERK in PDAC tissues, and a PERK inhibitor rescues the anti-proliferative effects of PUM1 knockdown, placing PUM1 upstream of the PERK/eIF2 pathway. siRNA knockdown; cDNA microarray and pathway analysis; Western blot; PERK inhibitor rescue experiments; in vitro and in vivo (xenograft) assays Cell death & disease Medium 31395860
2017 PUM1 acts as a negative regulator of innate immunity by repressing LGP2 expression. PUM1 depletion triggers a two-phase cascade: initial upregulation of LGP2, CXCL10, IL6, and PKR (phase 1), followed by upregulation of RIG-I, MDA5, IFIT1, IFNβ, and others (phase 2). Simultaneous depletion of PUM1 and LGP2 abrogates both phases, establishing LGP2 as the direct downstream mediator. PUM2 depletion does not reproduce these effects. siRNA knockdown of PUM1 alone and combinatorial knockdown of PUM1 + LGP2/CXCL10/IL6; RT-PCR for target gene expression; IFNβ functional assays; HSV-1 replication assay Proceedings of the National Academy of Sciences of the United States of America High 28760986
2022 PUM1 binds the 3' UTR of TLR4 mRNA to suppress its translation, thereby regulating NF-κB activity in human mesenchymal stem cells. PUM1 overexpression suppresses TLR4-mediated NF-κB signaling and protects against H2O2-induced senescence, while PUM1 knockdown activates TLR4-NF-κB signaling. The regulatory axis was confirmed in osteoarthritis models. RNA immunoprecipitation; 3' UTR binding assays; siRNA knockdown and overexpression; Western blot for TLR4 and NF-κB pathway; in vivo OA mouse model with lentiviral PUM1 gene therapy Cell death and differentiation High 35034101
2020 PUM1 mediates decay of 48 specific target mRNAs identified by combined transcriptome-wide mRNA stability profiling and PUM1 binding data. DNA-damaging agents (e.g., cisplatin) reduce PUM1 abundance, leading to stabilization of PCNA and UBE2A mRNAs (involved in translesion synthesis). PUM1 overexpression impairs DNA synthesis and TLS and increases cisplatin sensitivity. Transcriptome-wide mRNA stability profiling (metabolic labeling); RIP-seq; RNA-seq; PUM1 overexpression and knockdown; cisplatin sensitivity assays; DNA synthesis assays Cell reports High 32375027
2022 PUM1 directly binds γ-globin (HBG1) mRNA, reduces its stability and translational efficiency, thereby repressing fetal hemoglobin (HbF) production during erythroid differentiation. PUM1 expression is regulated by the erythroid transcription factor KLF1/EKLF and peaks during erythroid differentiation. PUM1 knockdown robustly increases HbF (~22%) without affecting β-globin levels. RNA immunoprecipitation (RIP); mRNA stability assays; translational efficiency assays; PUM1 knockdown in human erythroid cells; KLF1 regulation of PUM1 demonstrated; patient with heterozygous PUM1 RNA-binding domain mutation showing elevated HbF Blood advances High 35667093
2019 PUM1 directly binds the 3' UTR of LRP6 mRNA via RNA pull-down, RIP, and luciferase reporter assays, reducing LRP6 mRNA and protein expression. PUM1 repression of LRP6 restricts trophoblast proliferation and invasion; PUM1 depletion promotes these processes in an LRP6-dependent manner. RNA pull-down; RNA immunoprecipitation (RIP); luciferase reporter assay; RT-qPCR and Western blot; siRNA knockdown Biochemistry and cell biology Medium 34734756
2019 PUM1 inhibits trophoblast invasion in preeclampsia by binding HOTAIR lncRNA and decreasing its half-life (destabilizing HOTAIR mRNA). RNA-protein pull-down and mRNA stability assays identified PUM1 as a specific binding partner that reduces the steady-state level of HOTAIR, establishing a posttranscriptional regulatory mechanism. RNA immunoprecipitation (RIP); RNA-protein pull-down; mRNA stability assays; lncRNA transcriptome sequencing; overexpression and knockdown of PUM1; villous explant culture model Molecular therapy Medium 31862314
2021 PUM1 represses CDKN1B (p27) at the translational level in prostate cancer cells. PUM1 knockdown elevates CDKN1B protein without changing its mRNA level; PUM1 overexpression reduces CDKN1B protein. PUM1 knockdown in vivo reduces tumor size. siRNA knockdown and overexpression of PUM1; Western blot and RT-qPCR for CDKN1B; subcutaneous xenograft mouse model Journal of biomedical research Medium 34531333
2018 PUM1 exhibits PBE-independent repression of SIAH1 3' UTR (unlike PUM2 which requires PBEs), and the PUF domains of PUM1 and PUM2 show different EMSA complex formation patterns with SIAH1 3' UTRs. NANOS3 (but not NANOS2) directly binds SIAH1 3' UTR and cooperates with PUM1 in repression. Luciferase reporter assays with WT and PBE-mutant SIAH1 3' UTRs; EMSA (electrophoretic mobility shift assay); co-repression assays with NANOS paralogues Cellular and molecular life sciences Medium 30269240
2020 PUM1 and PUM2 form distinct RNP regulatory networks in human male germ cells (TCam-2), associating with different sets of protein cofactors (identified by mass spectrometry) and regulating partially overlapping but distinct mRNA pools (identified by RIP-Seq). This indicates functional divergence between the two paralogs despite highly similar RNA-binding domains. RIP-Seq; RNA-Seq; global mass spectrometry-based protein cofactor profiling; RNA motif enrichment analysis Cells Medium 32316190
2022 NANOS3 in complex with PUM1 causes 3' UTR-mediated repression of FOXM1 mRNA, which encodes a transcription factor required for G2/M phase transition. This establishes PUM1 as part of a NANOS3-PUM1 post-transcriptional repressor complex targeting FOXM1 to regulate G2/M progression in human primordial germ cells. RNA-sequencing; 3' UTR reporter assays; overexpression of NANOS3 and PUM1 in TCam-2 cells; cell cycle analysis International journal of molecular sciences Medium 35743036
2023 PUM1 binds directly to the Pumilio response element (PRE) in DEPTOR mRNA to maintain transcript stability (preventing its degradation), which leads to DEPTOR upregulation, mTORC1 inhibition, and relief of inhibitory feedback to PI3K, thus activating PI3K-Akt signaling and glycolysis in gastric cancer cells. RNA immunoprecipitation; RNA-sequencing; metabolomics; PUM1 knockdown in vitro and in vivo; Western blot for mTORC1/PI3K-Akt pathway components Advanced science Medium 37469018
2021 PUM1 interacts with DDX5 in the 3' UTR and positively regulates DDX5 mRNA expression in cetuximab-resistant colon cancer cells. PUM1 knockout reduced DDX5 levels and decreased cell viability in the presence of cetuximab. CRISPR-Cas9 knockout of PUM1 and DDX5; qPCR and immunoblot; co-immunoprecipitation; Cell Counting Kit-8 proliferation assay Frontiers in cell and developmental biology Low 34447749
2024 A chromosomal translocation creates a PUM1-TRAF3 fusion protein that activates non-canonical NF-κB signaling via competitive binding to NF-κB-inducing kinase (NIK), preventing TRAF3-mediated NIK degradation and enabling P52/RelB nuclear translocation. An NIK inhibitor reverses these effects. RNA-sequencing for fusion gene identification; FISH for validation; establishment of PUM1-TRAF3-expressing BTC cell lines; molecular pathway analysis; NIK inhibitor rescue experiments NPJ precision oncology Medium 39090283
2025 HIF1α transcriptionally activates PUM1 by directly binding its promoter under hypoxia. PUM1 then binds and destabilizes KCNK3 mRNA, reducing KCNK3 protein in pulmonary artery smooth muscle cells. In vivo AAV9-mediated PUM1 knockdown attenuated pulmonary hypertension, while PUM1 overexpression exacerbated it. HIF1α knockdown increased KCNK3 mRNA stability and reduced PUM1-KCNK3 mRNA interaction. ChIP for HIF1α binding to PUM1 promoter; RIP for PUM1-KCNK3 mRNA interaction; mRNA stability assays; AAV9-mediated in vivo knockdown; overexpression experiments; rat PH models Biochimica et biophysica acta. Molecular basis of disease Medium 41135634
2025 PUM1-mediated mRNA decay requires the CCR4-NOT deadenylase complex (not the PAN deadenylase) and depends on the poly(A) tail. PUM1 associates with and requires PABPC1 and PABPC4 to repress target mRNAs. Increasing PABPC concentration inhibits PUM1 activity in a concentration-dependent manner by protecting poly(A) from deadenylation, establishing a tunable regulatory mechanism. Biochemical reconstitution; deadenylase requirement assays; PABPC co-immunoprecipitation; PABPC titration experiments; mRNA decay assays bioRxiv (preprint)preprint Medium bio_10.1101_2025.10.02.680050
2024 PUM1 binds CCR4-NOT through intrinsically disordered regions (IDRs) via multivalent interactions at several distinct binding sites. Phosphorylation within IDRs modulates PUM1 binding to CCR4-NOT and consequently tunes the mRNA deadenylation rate in a continuously graded (not binary) manner, as demonstrated by biochemical reconstitution and structural analysis. Structural biology; biochemical reconstitution; phosphorylation-dependent binding assays; in vitro deadenylation assays with WT and phosphomimetic/phosphoablative PUM1 IDR variants bioRxiv (preprint)preprint Medium bio_10.1101_2024.10.18.618793
2025 PUM1 enhances PAK6 mRNA stability by binding to PAK6 mRNA (demonstrated by RIP and luciferase assay), thereby promoting ferroptosis resistance in lung adenocarcinoma cells. PUM1 silencing promotes ferroptosis both in vitro and in vivo, and this effect is reversed by artificial restoration of PAK6. RNA immunoprecipitation; luciferase assay; PUM1/PAK6 knockdown; ferroptosis assays (Fe2+, MDA levels); in vivo xenograft model Pathology, research and practice Medium 40694989
2014 PUM1 silencing in pancreatic cancer cells increases p27 (CDKN1B) expression and the amount of the p27-CDK2 complex, as shown by immunoprecipitation. PUM1 overexpression attenuates TRAIL-induced effects, while PUM1 silencing enhances autophagy activation and TRAIL sensitivity. siRNA knockdown; immunoprecipitation (p27-CDK2 complex); Western blot; proliferation and apoptosis assays; in vivo xenograft Phytomedicine Low 31128486
2023 PUM1 regulates macrophage polarization via the PUM1/Cripto-1 pathway: PUM1 negatively regulates Cripto-1 expression and promotes M1-type macrophage polarization. Allogeneic blood transfusion inhibits ferroptosis in macrophages through effects on this pathway. RT-qPCR; Western blot; in vivo mouse model; in vitro RAW264.7 cell experiments; macrophage polarization marker analysis; JC-1 staining Aging Low 37387538
2025 PUM1 depletion mildly increases intracellular SARS-CoV-2 viral RNA levels, suggesting a mild antiviral or host-factor regulatory role. PUM1 also negatively regulates innate immunity gene expression both at steady state and during SARS-CoV-2 infection. However, altering PUM1 levels does not affect progeny virion production. siRNA/shRNA depletion; viral RNA quantification; innate immunity gene expression assays; progeny virion production assays (plaque/TCID50) The Journal of general virology Medium 40956600

Source papers

Stage 0 corpus · 54 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Ribonomic analysis of human Pum1 reveals cis-trans conservation across species despite evolution of diverse mRNA target sets. Molecular and cellular biology 132 18411299
2018 A Mild PUM1 Mutation Is Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and Seizures. Cell 111 29474920
2002 Cloning and comparative sequence analysis of PUM1 and PUM2 genes, human members of the Pumilio family of RNA-binding proteins. Gene 78 12459267
2022 TLR4 downregulation by the RNA-binding protein PUM1 alleviates cellular aging and osteoarthritis. Cell death and differentiation 74 35034101
2020 Circ_PUM1 promotes the development of endometrial cancer by targeting the miR-136/NOTCH3 pathway. Journal of cellular and molecular medicine 55 32073729
2003 Mouse Pum1 and Pum2 genes, members of the Pumilio family of RNA-binding proteins, show differential expression in fetal and adult hematopoietic stem cells and progenitors. Blood cells, molecules & diseases 54 12667987
2019 Mammalian Pum1 and Pum2 Control Body Size via Translational Regulation of the Cell Cycle Inhibitor Cdkn1b. Cell reports 48 30811992
2019 PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. Cell death & disease 42 31395860
2018 PUM1 promotes ovarian cancer proliferation, migration and invasion. Biochemical and biophysical research communications 39 29428722
2019 Upregulation of PUM1 Expression in Preeclampsia Impairs Trophoblast Invasion by Negatively Regulating the Expression of the lncRNA HOTAIR. Molecular therapy : the journal of the American Society of Gene Therapy 37 31862314
2017 PUM1 is a biphasic negative regulator of innate immunity genes by suppressing LGP2. Proceedings of the National Academy of Sciences of the United States of America 34 28760986
2023 PUM1 Promotes Tumor Progression by Activating DEPTOR-Meditated Glycolysis in Gastric Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 31 37469018
2018 MiR-411-5p acts as a tumor suppressor in non-small cell lung cancer through targeting PUM1. European review for medical and pharmacological sciences 28 30229827
2019 Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. Phytomedicine : international journal of phytotherapy and phytopharmacology 25 31128486
2021 RNA binding protein PUM1 promotes colon cancer cell proliferation and migration. International journal of biological macromolecules 23 33508364
2021 Long non-coding RNA NORAD inhibition upregulates microRNA-323a-3p to suppress tumorigenesis and development of breast cancer through the PUM1/eIF2 axis. Cell cycle (Georgetown, Tex.) 23 34125645
2021 Circular RNA PUM1 (CircPUM1) attenuates trophoblast cell dysfunction and inflammation in recurrent spontaneous abortion via the MicroRNA-30a-5p (miR-30a-5p)/JUNB axis. Bioengineered 21 34519628
2020 Systematic Analysis of Targets of Pumilio-Mediated mRNA Decay Reveals that PUM1 Repression by DNA Damage Activates Translesion Synthesis. Cell reports 21 32375027
2020 Novel three-way complex rearrangement of TRPM1-PUM1-LCK in a case of agminated Spitz nevi arising in a giant congenital hyperpigmented macule. Pigment cell & melanoma research 20 32386465
2020 Gene-gene and gene-lifestyle interactions of AKAP11, KCNMA1, PUM1, SPTBN1, and EPDR1 on osteoporosis risk in middle-aged adults. Nutrition (Burbank, Los Angeles County, Calif.) 19 32619791
2010 A structural-based statistical approach suggests a cooperative activity of PUM1 and miR-410 in human 3'-untranslated regions. Silence 19 20860814
2022 Morin inhibits colon cancer stem cells by inhibiting PUM1 expression in vitro. Medical oncology (Northwood, London, England) 16 36224472
2018 PUM1 and PUM2 exhibit different modes of regulation for SIAH1 that involve cooperativity with NANOS paralogues. Cellular and molecular life sciences : CMLS 16 30269240
2016 Morphotype-specific effector functions of Cryptococcus neoformans PUM1. Scientific reports 14 27008977
2022 PUM1 mediates the posttranscriptional regulation of human fetal hemoglobin. Blood advances 13 35667093
2021 PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab. Frontiers in cell and developmental biology 13 34447749
2020 Characterization of RNP Networks of PUM1 and PUM2 Post-Transcriptional Regulators in TCam-2 Cells, a Human Male Germ Cell Model. Cells 12 32316190
2021 Silencing of circular RNA PUM1 inhibits clear cell renal cell carcinoma progression through the miR-340-5p/FABP7 axis. Journal of receptor and signal transduction research 11 33472512
2015 Loss of preimplantation embryo resulting from a Pum1 gene trap mutation. Biochemical and biophysical research communications 11 25896760
2023 Inducing Cytotoxicity in Colon Cancer Cells and Suppressing Cancer Stem Cells by Dolasetron and Ketoprofen through Inhibition of RNA Binding Protein PUM1. Toxics 10 37624174
2022 Circular RNA PUM1 performs as a competing endogenous RNA of microRNA-340-5p to mediate DEAD-box helicase 5 to mitigate cerebral ischemia-reperfusion injury. Bioengineered 10 35510394
2022 Distinct Roles of NANOS1 and NANOS3 in the Cell Cycle and NANOS3-PUM1-FOXM1 Axis to Control G2/M Phase in a Human Primordial Germ Cell Model. International journal of molecular sciences 10 35743036
2021 PUM1 represses CDKN1B translation and contributes to prostate cancer progression. Journal of biomedical research 10 34531333
2023 Exosome-mediated circGMPS facilitates the development of gastric cancer cells through miR-144-3p/PUM1. Cytotechnology 8 38304630
2021 PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer. Journal of clinical laboratory analysis 7 33522650
2019 Investigating PUM1 mutations in a Taiwanese cohort with cerebellar ataxia. Parkinsonism & related disorders 7 31422002
2023 PUF-8, a C. elegans ortholog of the RNA-binding proteins PUM1 and PUM2, is required for robustness of the cell death fate. Development (Cambridge, England) 5 37747106
2011 Spatial-temporal expression of pum1 and pum2 in medaka Oryzias latipes. Journal of fish biology 5 22220892
2024 PUM1-TRAF3 fusion protein activates non-canonical NF-κB signaling via rescued NIK in biliary tract cancer. NPJ precision oncology 4 39090283
2023 Up-regulation of PUM1 by miR-218-5p promotes colorectal tumor-initiating cell properties and tumorigenesis by regulating the PI3K/AKT axis. Journal of gastrointestinal oncology 4 36915463
2021 PUM1 modulates trophoblast cell proliferation and migration through LRP6. Biochemistry and cell biology = Biochimie et biologie cellulaire 4 34734756
2018 Variation analysis of PUM1 gene in Chinese women with primary ovarian insufficiency. Journal of assisted reproduction and genetics 3 29297114
2024 PUM1 and PGK1 are Favorable Housekeeping Genes over Established Biodosimetry-related Housekeeping Genes such as HPRT1, ITFG1, DPM1, MRPS5, 18S rRNA and Others after Radiation Exposure. Radiation research 2 38471523
2022 A de novo PUM1 Variant in a Girl With a Dravet-Like Syndrome: Case Report and Literature Review. Frontiers in pediatrics 2 35386260
2025 A new developmental and epileptic encephalopathy: PUM1-neurodevelopmental disorder with epilepsy with myoclonic-atonic seizures. Seizure 1 40472467
2025 PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production. The Journal of general virology 1 40956600
2025 The HIF1α-PUM1-KCNK3 axis drives pulmonary hypertension by destabilizing KCNK3 mRNA in pulmonary artery smooth muscle cells. Biochimica et biophysica acta. Molecular basis of disease 1 41135634
2023 Exploration of the effect of PUM1/Cripto-1 pathway on ferroptosis by regulating macrophage polarization in allogeneic blood transfused mice. Aging 1 37387538
2026 Evaluation of the circular RNA Pum1_0014, miRNA-146a, and miRNA-141-3p as biomarkers in PCOS. Journal of Taibah University Medical Sciences 0 41908224
2026 Fusobacterium nucleatum drives colorectal cancer progression through the circPTBP3/miR-760/PUM1 axis. Oncogene 0 41912775
2025 PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production. bioRxiv : the preprint server for biology 0 40666984
2025 PUM1 enhances PAK6 mRNA stability and contributes to growth and ferroptosis resistance in lung adenocarcinoma cells. Pathology, research and practice 0 40694989
2025 Retraction Note: MiR-411-5p acts as a tumor suppressor in non-small cell lung cancer through targeting PUM1. European review for medical and pharmacological sciences 0 41342067
2020 Repression of PUM1-mediated mRNA decay activates translesion synthesis after DNA damage. Molecular & cellular oncology 0 33241107

Missed literature

Know a paper Affinage missed for PUM1? Flag it for the maintainers and the community.

No submissions yet.